Objective: Current practice guidelines do not recommend benzodiazepines for acute management of anxiety disorders in pediatric patients. However, in procedural settings, benzodiazepines are commonly used to relieve acute preprocedural stress. This meta-analysis examines the efficacy and tolerability of benzodiazepines as short-term anxiolytics in children.
INTRODUCTION
When confronted with acute stressors (e.g., surgical or dental procedures), healthy children may experience acute anxiety attacks, characterized by intense motor and visceral activation, as well as distortions of perception, loss of concentration, and impaired memory resulting in temporary debilitation (Sadock, Sadock, & Ruiz, 2015) .
Preoperative anxiety has been associated with postprocedural psychological and behavioral problems in children, including separation anxiety, eating anxiety, apathy, withdrawal, sleep problems, and aggression toward authority (Kain, Mayes, O'Connor, & Cicchetti, 1996) . Though generally short-lived, these maladaptive behaviors are nevertheless distressing and counterproductive to the recovery process in immediate postprocedure periods.
Although the use of benzodiazepines for the treatment of anxiety disorders and acute anxiety in adults is robust (Bandelow et al., 2015; Hidalgo, Tupler, & Davidson, 2007; Nardi & Perna, 2006) , limited research exists regarding the effects of benzodiazepines in pediatric populations. Due to the concern for developing dependence and the lack of established efficacy studies (Riddle et al., 1999) , the use of benzodiazepines for anxiety in children is limited mostly to the use of short-acting agents (e.g., midazolam) as sedatives prior to surgical or dental procedures. The goal of this meta-analysis is to examine the efficacy of benzodiazepines as acute anxiolytics in pediatric populations in randomized, placebo-controlled trials. 
METHODS

Search strategy
Three reviewers searched PubMed (1965 -Aug 22, 2016 for relevant citations. Within PubMed, the search strategy ("Benzodiazepines" [Mesh] and "Anxiety" [Mesh] or "Anxiety Disorders" [Mesh]) and (Randomized Controlled Trial[ptyp] and ("infant" [MeSH Terms] or "child"[MeSH Terms] OR "adolescent"[MeSH Terms])) was used. There were no language limitations in this initial search stage.
Inclusion/exclusion criteria
Trials were included in the meta-analysis if they were blinded randomized controlled trials (RCT) that assessed the efficacy of benzodiazepines for short-term anxiety in the pediatric population (age less than 18 years). Trials that involved adult populations or mixed adult/pediatric populations were excluded. Included trials were required to have reported the mean numerical measurements of anxiety levels in both the treatment and control groups. Trials were required to measure anxiety specifically as an outcome. Trials that used rating scales to measure sedation rather than anxiety (e.g., Ramsey Sedation Scale) were excluded. Trials included had to have examined the acute anxiolytic effects of benzodiazepines. Trials that examined the effects of benzodiazepines on anxiety for longer than 1 day were excluded. Additionally, all RCTs were included if an inactive control condition (placebo or no placebo) was present. Trials that included an active control condition (e.g., parental presence, clowns, behavioral training), not also given to the benzodiazepine group, were excluded.
Studies written in a language other than English were also excluded.
Meta-analytic procedures
To extract data from included articles, customized Microsoft Excel spreadsheets were used. Data extracted included the type of benzodiazepine (midazolam or not midazolam), the route of administration (intranasal, intravenous, oral or rectal), the dose (in mg/kg), and the diazepam dose equivalent per kilogram, the timing of administration (in minutes prior to stressful event), the indication for benzodiazepine use (dental, operating room, or nonsurgical procedure), sample size, mean age of treatment and control groups, the types of outcomes rating scales used, and the timing of the endpoint measurement.
The primary outcome measure was the endpoint score on the anxiety rating scale used in the trial. Rating scales that measured sedation rather than anxiety were not included in the meta-analysis. The difference in anxiety levels between the benzodiazepine groups and the control groups was calculated as the standardized mean difference (SMD) using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, New Jersey). This measure was favored over weighted mean difference because rating scales differed between the included studies. As there was some evidence of publication bias, a fixed-effect model was used for this meta-analysis. A fixed-effects model is considered more conservative in the case of publication bias because it gives less weight to smaller studies that are more prone to publication bias. Publication bias was assessed by plotting the effect size against standard error for each trial (i.e., a funnel plot). In addition, publication bias was statistically tested by the Egger test. Heterogeneity between trials was determined by Q-statistic and I 2 statistic.
For secondary analysis, a stratified subgroup analysis was conducted using comprehensive meta-analysis to assess the effects of (1) type of benzodiazepine (midazolam, not midazolam), (2) type of control condition (placebo, no placebo), (3) route of administration (oral, intranasal, intravenous, rectal), (4) setting of administration (dental, operating room, nonoperating room). For trials that examined oral midazolam, an additional metaregression examining the effects of dose and timing of medication was performed. The threshold for statistical significance was selected to be P < .05 for all analyses.
RESULTS
Included trials
Twenty-one trials involving 1,416 participants were included in this meta-analysis (Eskandarian, Arabzade Moghadam, Reza Ghaemi, & Bayani, 2015; Fatovich & Jacobs, 1995; Ferguson et al., 2011; Finley, Stewart, Buffett-Jerrott, Wright, & Millington, 2006; Gallardo, Cornejo, & Borie, 1994; Gillerman, Hinkle, Green, Cornell, & Dodge, 1996; Golan, Tighe, Dobija, Perel, & Keidan, 2009; Heden, von Essen, Frykholm, & Ljungman, 2009; Hennes et al., 1990; Herd, McAnulty, Keene, & Sommerville, 2006; Hosseini Jahromi, Hosseini Valami, Adeli, & Yazdi, 2012; Kain et al., 2004 Kain et al., , 2000 Lan, Huang, Finley, & Zuo, 2012; McCluskey & Meakin, 1994; Riva et al., 1997; Samarkandi et al., 2005; Shane, Fuchs, & Khine, 1994; Templeton et al., 2010; Vagnoli, Caprilli, & Messeri, 2010; Vetter, 1993) . Figure 1 depicts the algorithm for selection of the included trials. Twenty-four treatment arms were included from the 21 eligible studies. Eighteen trials compared the use of a benzodiazepine with the use of a placebo, while three trials did not use a placebo (Golan et al., 2009; Kain et al., 2004; Vagnoli et al., 2010) . All 21 trials used midazolam as the treatment medication. One of the trials also had a treatment arm using diazepam as the medication (Vetter, 1993) . The setting of benzodiazepine use was dental procedure in 2 trials (Eskandarian et al., 2015; Gallardo et al., 1994) , operating room procedure in 14 trials (Ferguson et al., 2011; Finley et al., 2006; Gillerman et al., 1996; Golan et al., 2009; Hosseini Jahromi et al., 2012; Kain et al., 2004 Kain et al., , 2000 Lan et al., 2012; McCluskey & Meakin, 1994; Riva et al., 1997; Samarkandi et al., 2005; Templeton et al., 2010; Vagnoli et al., 2010; Vetter, 1993) , and nonoperating room procedure in five trials (Fatovich & Jacobs, 1995; Heden et al., 2009; Hennes et al., 1990; Herd et al., 2006; Shane et al., 1994; ) 
Efficacy of benzodiazepines in the treatment of acute anxiety
Moderators of benzodiazepine efficacy in the treatment of acute anxiety
The type of benzodiazepine was not significantly associated with the efficacy of therapy (test for subgroup differences: Q 1 = 0.94, P = .33). The setting in which benzodiazepines were used was significantly associated with efficacy of therapy (test for subgroup differences: Q 2 = 6.34, P = .04). Trials done in the setting of dental (SMD = ROA, route of administration; min before, minutes before stressful event; OR, operating room.
Midazolam (SMD
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Forest plot: efficacy of benzodiazepines as short-term anxiolytics in pediatric patients. This plot shows mean standardized difference in anxiety levels of subjects given benzodiazepine premedication compared to subjects given the control condition. Overall, benzodiazepine treatment was more efficacious than control (SMD = 0.71 [95% confidence interval (CI), 0.60-0.82], k = 24, z = 12.7, P < .001). There was significant heterogeneity between trials (Q 23 = 48.07, P = .002, I 2 = 52.15%) and some evidence of publication bias 
Tolerability
Side effects of benzodiazepine treatment were sparsely reported by included trials and other trials using benzodiazepines in acute pro- in subjects assigned to midazolam compared to placebo. Behavioral changes and irritability were examined in five trials involving 215 subjects (Heden et al., 2009; McCluskey & Meakin, 1994; Shane et al., 1994; Templeton et al., 2010; Wan et al., 2006) . Benzodiazepine use was associated with a similar risk of irritability/behavioral changes compared to placebo (RR = 0.74, 95% CI, 0.51-1.06, z = −1.63, P = .10).
Other adverse effects were also reported, including nausea/vomiting (Heden et al., 2009; Isik et al., 2008; Shane et al., 1994) and respiratory depression (Herd et al., 2006 ), but were not significantly different between benzodiazepines and placebo arms in individual studies.
DISCUSSION
This meta-analysis demonstrated that benzodiazepines are signifi- Although this meta-analysis indicates that benzodiazepines are effective as a short-term anxiolytic in procedural settings, there is evidence in the literature to support the efficacy of behavioral treatments for the reduction of acute anxiety in procedural settings as well (Berbel, Moix, & Quintana, 2007; Chow, Van Lieshout, Schmidt, Dobson, & Buckley, 2016; Dionigi & Gremigni, 2016; Kain et al., 2004) .
Parental presence and the use of clowns (who are specially trained to perform music and magic in the hospital setting) were demonstrated to be effective in reducing a child's preoperative anxiety level (Capurso & Ragni, 2016; Dionigi & Gremigni, 2016; Golan et al., 2009; Vagnoli et al., 2010) . Various methods of distraction, including art therapy (Dionigi & Gremigni, 2016) , video games (Chow et al., 2016) , and music (Berbel, Moix, & Quintana, 2007; Kain et al., 2004) , have also been examined as methods to reduce preprocedural anxiety. When confronting acute psychiatric and intermittent anxiety conditions, behavioral treatments should be the preferred approach. In these settings, cognitive behavioral therapy (CBT) focuses on techniques for managing somatic reactions, identifying anxiety triggers, and desensitization to feared stimuli, and has been shown to be effective for children and adolescents with social anxiety disorder (Scaini, Belotti, Ogliari, & Battaglia, 2016) . A 2015 review also found robust evidence for an effective acute response to CBT in children with various anxiety disorders (Wehry, Beesdo-Baum, Hennelly, Connolly, & Strawn, 2015) . However, the role of benzodiazepines as an adjunct pharmacotherapy to CBT for anxiety disorders has yet not been thoroughly investigated, thus it is yet unclear whether they would be useful as adjunctive therapy to behavioral treatments in acute procedural settings.
The results of this meta-analysis may have relevance for the treatment of anxiety disorders in children. Previous research on the effects of benzodiazepines as an anxiolytic in children with anxiety disorders is sparse and severely underpowered. Additionally, antiquated diagnostic criteria and rating scales have been used to examine anxiety outcomes (Bernstein, Garfinkel, & Borchardt, 1990; Graae, Milner, Rizzotto, & Klein, 1994; Simeon et al., 1992) . Small, randomized, placebocontrolled trials have failed to demonstrate a significant benefit of alprazolam for anxiety in school refusal (n = 24) and overanxious or avoidant disorders (n = 30) (Simeon et al., 1992) and clonazepam for mixed anxiety disorders in children (n = 15; Graae et al., 1994) . These three trials have also reported generally mild, nonimpairing side effects of benzodiazepines including dry mouth, drowsiness, fatigue, blurred vision, abdominal pain, headache, and dizziness, but have not demonstrated a statistically significant higher risk of such side effects compared to placebo (Bernstein et al., 1990; Graae et al., 1994; Simeon et al., 1992) . The trial involving clonazepam reported two children discontinued the study medication due to worsened disinhibition, oppositional behavior, and irritability (Graae et al., 1994) . Based on this sparse data, a Cochrane Review appropriately concluded that "no controlled evidence could be found for the efficacy of benzodiazepines to warrant their increased prescription for pediatric patients." This review also voiced concerns regarding adverse effects (including disinhibition) and the potential for dependence with benzodiazepine use (Ipser, Stein, Hawkridge, & Hoppe, 2009 ). Thus, though the tolerability analysis of benzodiazepines used acutely in procedural settings has revealed no significant side effects, it is unclear how generalizable these findings will be to the treatment of acute pediatric anxiety and agitation where the dosing of benzodiazepines is likely to be more conservative and the medications may be used to treat anxiety repeatedly and for a longer duration of time.
Evidence-based treatment for anxiety disorders includes cognitive behavioral therapies (CBTs) and pharmacotherapy, both of which have proven efficacy and are most effective when used in combination (Walkup et al., 2008) . CBT for anxiety generally focus on desen- , 1997) . Another meta-analysis found benzodiazepines to be significantly more efficacious than placebo in the short-term management of generalized anxiety disorder (Martin et al., 2007) .
Benzodiazepines are commonly used in adult populations to provide anxiolytic effect in the first weeks of SSRI therapy when the therapeutic SSRI dose has not yet been reached. Because of the risk of dependence and of cognitive impairment with chronic use, benzodiazepines are generally not recommended as a standing medication for the long-term treatment of anxiety (Sadock et al., 2015) . Given similar risks in pediatric populations, benzodiazepines are additionally not recommended for the long-term treatment of anxiety in children. Benzodiazepines, however, may have two other potential uses, including
(1) an adjunctive as-needed medication to manage crippling intermittent anxiety that leads to severe adverse consequences in children refractory to evidence-based pharmacotherapy and psychotherapy, and (2) to manage acute anxiety and aggressive behavior in a severely impaired pediatric anxiety population, especially on an inpatient setting as an alternative to off-label use of atypical antipsychotics. Based on the limited tolerability data in this analysis, benzodiazepines appear to have a more favorable side effect profile than atypical antipsychotics, as studies have shown atypical antipsychotics to be associated with weight gain, new-onset diabetes, increased risk of arrhythmia, and extrapyramidal symptoms (McDonagh, Peterson, Carson, Fu, & Thakurta, 2010) . In pediatric patients, the risks of such side effects must be weighed carefully, as greater interpatient heterogeneity in pharmacokinetics makes it difficult to predict the bioavailability of the antipsychotic medications (Caccia, 2013) . However, given that reporting of benzodiazepine side-effect data is sparse and inconsistent in available trials and that when reported, side-effects were mostly assessed in a subjective manner, a more methodically rigorous, high-powered RCT would be needed to clearly elucidate the safety of short-term benzodiazepine use as an alternative to antipsychotics and other augmentation strategies in SSRI-refractory children with anxiety disorders. In the interim, we would recommend for procedures likely to produce significant anxiety that clinicians consider a safe and effective treatment. Additionally, clinicians treating children experiencing acute anxiety symptoms (e.g. short-term treatment of severe panic attacks, separation anxiety or OCD symptoms) should view benzodiazepines as a potentially beneficial treatment option that can be considered in lieu of antipsychotic medications or primarily sedating medications (diphenhydramine or trazodone). We would recommend that behavioral therapies and techniques be used preferentially to medications as they have better evidence of efficacy and do not have the side-effect concerns of these other agents (including benzodiazepines).
Given the important findings of this meta-analysis, it is important to acknowledge several limitations in this study. The data consisted of a fairly small number of trials, especially those involving benzodiazepines other than midazolam. Even though a difference in effect size between midazolam and other benzodiazepines utilized was not shown, the small number of nonmidazolam studies limits the generalizability of these findings to other agents. There was also funnel plot asymmetry in this meta-analysis, suggesting some evidence of publication bias. The effects of benzodiazepines as acute anxiolytics remained significant even after controlling for funnel plot asymmetry. Additionally, there was a large amount of heterogeneity between trials. Several subgroup analyses and meta-regressions were conducted to understand the sources of this heterogeneity, but given the small number of trials, the associations were underpowered.
This meta-analysis suggests that benzodiazepine use is quite effective as a short-term anxiolytic for children in procedural settings and is well tolerated in this context. Trials examining the use of benzodiazepines in pediatric anxiety disorders are quite sparse, underpowered, and subject of antiquated diagnostic constructs of anxiety.
Further research would be useful to examine the acute effects of benzodiazepines for anxiety in inpatient settings and as an adjunctive as-needed treatment in children with severe anxiety that has failed to improve substantially with optimal medication management and CBT.
It would also be worth investigating whether benzodiazepines significantly interfere with the efficacy of CBT in the pediatric population, as existing literature suggests there is a detrimental effect of high potency benzodiazepines on CBT efficacy for anxiety in adults (Westra & Stewart, 1998) . The data surrounding the strong discouragement of benzodiazepine use in pediatric anxiety disorders seems weak when considering (1) the strong data for allied pediatric professions suggesting potential efficacy and reasonable tolerability demonstrated in this meta-analysis and (2) that often off-label use of antipsychotics is the alternative available treatment in these children with acute anxiety. 
